Insight Molecular Diagnostics Presents GraftAssure Rollout Plans With Seven US Centers in Validation
- Insight Molecular Diagnostics has seven U.S. transplant centers validating GraftAssure, with launches expected in 2027.
- These centers represent about 7% of annual U.S. kidney transplant volume, supporting an annual revenue target above $15 million at steady state.
- GraftAssureDx remains under FDA review for commercial use following its March 2026 submission.
- Medicare reimbursement for GraftAssureCore is $2,753 per result, supporting the strategy to move transplant testing into local laboratories.
- Bio-Rad is a top-five shareholder following four equity investments; GraftAssure assays run on its instruments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.